Home Infusion for Rheumatoid Arthritis: Remicade, Biologics, and What to Expect

Rheumatoid arthritis (RA) is a chronic autoimmune disease that causes joint inflammation, pain, and progressive damage if not adequately treated. For patients with moderate-to-severe RA who have not responded to conventional disease-modifying drugs (DMARDs), IV biologic therapies, most commonly Remicade (infliximab), are a cornerstone of long-term disease management.

Receiving these infusions through home infusion therapy is an established option for appropriate patients, eliminating the need for repeated trips to an infusion center. Pharmko provides IV biologic therapy for rheumatoid arthritis across 22+ states with full nursing and clinical support.

How IV Biologics Work for Rheumatoid Arthritis

Biologic medications for RA are engineered proteins that target specific components of the immune response driving joint inflammation. Unlike conventional DMARDs (methotrexate, hydroxychloroquine), which suppress the immune system broadly, biologics block precise inflammatory pathways, allowing for more targeted disease control with a different side effect profile.

The most common IV biologics used in rheumatoid arthritis include:

Remicade (infliximab)

Remicade targets tumor necrosis factor-alpha (TNF-α), a key driver of joint inflammation in RA. It is given by IV infusion at weeks 0, 2, and 6 for induction, then every 8 weeks for maintenance. Remicade is often combined with methotrexate to reduce the formation of anti-drug antibodies and improve long-term efficacy.

Orencia (abatacept)

Orencia works differently from TNF inhibitors, it blocks T-cell activation, an earlier step in the inflammatory cascade. It is administered monthly by IV infusion after a loading dose schedule at weeks 0, 2, and 4. Orencia is often preferred for patients who have not responded to or tolerated TNF inhibitors.

Actemra (tocilizumab)

Actemra targets the interleukin-6 (IL-6) receptor, blocking a cytokine that plays a central role in RA inflammation and systemic symptoms including fatigue and anemia of chronic disease. It is given every 4 weeks by IV infusion. Actemra is also used as monotherapy (without methotrexate) in patients who cannot tolerate conventional DMARDs.

Who Qualifies for Home Infusion of IV Biologics for RA?

Home infusion of IV biologics for rheumatoid arthritis is appropriate for patients who:

Have received at least their first two to three infusions in a supervised clinical or infusion center setting to screen for infusion reactions
Are on a stable, maintenance dose without recent significant reactions
Have been assessed by their rheumatologist as clinically stable for home-based administration
Have a home environment that supports safe IV administration

Patients who are newly starting a biologic, have a history of serious infusion reactions, or have active infection or significant immunosuppression typically require supervised infusions until their clinical situation is established.

What a Home Biologic Infusion for RA Looks Like

Before the infusion

Your rheumatologist confirms your next infusion is due and submits orders to Pharmko. Our team verifies your insurance coverage, prepares your medication, and schedules a nursing visit. Before the infusion begins, your Pharmko nurse reviews your current medications, checks for signs of active infection, and takes baseline vital signs. Pre-medications (acetaminophen, antihistamine, or corticosteroid) may be given per your rheumatologist's orders.

During the infusion

Infusion duration varies by medication: Remicade typically takes 2 hours, Orencia approximately 30 minutes, and Actemra about 1 hour. Your nurse monitors your vital signs throughout and is present to respond immediately to any reaction. The rate may be slowed if you experience any discomfort.

After the infusion

Your nurse documents the session and communicates with your rheumatologist's office. You will be monitored briefly before the nurse leaves. Know which symptoms should prompt a call in the hours and days after your infusion, delayed reactions can occur with biologics, and our 24/7 after-hours support line is available around the clock.

Managing Infection Risk on IV Biologics

All IV biologics used in RA suppress components of the immune system, which increases susceptibility to infection. Before starting or continuing biologic therapy, your rheumatologist will typically screen for tuberculosis, hepatitis B, and ensure vaccinations are up to date.

During home infusion therapy, contact Pharmko immediately if you develop fever, new respiratory symptoms, skin infections, or any symptoms that seem unusual. Do not wait until your next scheduled infusion. Infection risk is one of the primary reasons biologics require ongoing clinical supervision even when administered at home.

Remicade for RA vs Crohn's Disease

Remicade is FDA-approved for both rheumatoid arthritis and inflammatory bowel disease. While the mechanism is the same, TNF-α inhibition, the dosing, monitoring, and clinical context differ between these indications. For patients managing both RA and GI conditions, or for providers comparing these use cases, our guide on home infusion for Crohn's disease covers the IBD-specific context in detail. A broader overview of IV biologics across autoimmune conditions is available in our article on home infusion for autoimmune diseases.

Insurance Coverage for Home Biologic Infusions

IV biologics for rheumatoid arthritis are typically covered under the medical benefit — not the pharmacy benefit — by Medicare Part B and most commercial insurance plans when administered by a licensed provider. Prior authorization is required and must document clinical indication, prior DMARD history, and current disease activity. Pharmko manages the full authorization process and will communicate any coverage concerns before your first home infusion.

Step therapy requirements, where insurers require trial and failure of less expensive agents before approving a biologic, are common. Pharmko's authorization team is experienced with RA-specific step therapy documentation and can support your rheumatologist in building the necessary clinical record.

Getting Started

If you or your patient is on a stable IV biologic for rheumatoid arthritis and interested in transitioning to home infusion, the first step is a referral from your rheumatologist. Pharmko works with rheumatology practices across 22+ states and can typically initiate therapy within 24–72 hours of referral acceptance.

→ Submit a referral or contact Pharmko : 1-877-540-2003 · info@pharmko.com

< Older Post

USP 797 and USP 800: What Patients and Providers Should Know About Sterile Compounding Safety

May 26, 2026

When a patient or provider chooses a compounding pharmacy to prepare IV medications, they are trusting that the pharmacy operates under rigorous, independently enforced standards. In the United States, those standards are defined by two chapters of the United States Pharmacopeia: USP <797> for sterile compounding and USP <800> for hazardous drug handling. Pharmko operates in full compliance with both chapters. Understanding what these standards require, and what happens when they are not met, helps patients and providers make informed decisions about which pharmacy they trust with their care. What Is USP <797>? USP <797> (Pharmaceutical Compounding, Sterile Preparations) is the national standard that defines the minimum requirements for compounding sterile preparations safely. It covers: Cleanroom environment classification, ISO Class 5 at the point of compounding, ISO Class 7 for the surrounding buffer area, ISO Class 8 for the ante-room Personnel training, gowning, and aseptic technique requirements Sterilization and filtration methods by product type Beyond-use dating (BUD), how long a compounded sterile preparation remains safe to use Environmental and personnel monitoring schedules Quality assurance, documentation, and deviation management USP <797> applies to every pharmacy that prepares IV solutions, injections, eye drops, or other sterile preparations, whether they are a hospital pharmacy, ambulatory infusion center, or specialty pharmacy like Pharmko. The 2023 Revision: What Changed USP <797> was significantly revised in 2023 (effective November 2023). Key changes include: Stricter beyond-use date requirements, compounded sterile preparations must now meet more conservative dating limits unless sterility testing supports extended dating Enhanced environmental monitoring, more frequent air and surface sampling with defined action levels Clearer personnel qualification requirements, competency assessments are now required at defined intervals New category system, preparations are now categorized (Category 1 and Category 2) based on sterility assurance level and BUD Pharmacies that were compliant under the previous version of USP <797> must have updated their procedures and infrastructure to meet the 2023 revision. Pharmko updated our facilities, policies, and documentation systems in alignment with the revised chapter. What Is USP <800>? USP <800> (Pharmaceutical Compounding, Hazardous Drugs) establishes standards for the safe handling of hazardous drugs throughout the pharmacy, from receipt and storage to preparation, dispensing, and waste disposal. Hazardous drugs include certain chemotherapy agents, antiviral medications, hormones, and other drugs that pose risks of carcinogenicity, reproductive toxicity, or organ damage at low exposure levels. USP <800> requires: Negative-pressure ventilated containment primary engineering controls (C-PECs) for hazardous drug compounding Separate, dedicated hazardous drug storage areas Personal protective equipment (PPE) requirements for all staff handling hazardous drugs Closed-system drug transfer devices (CSTDs) for certain preparations Spill kits and exposure management protocols Why These Standards Matter for Patients The consequences of non-compliance are serious. High-profile compounding pharmacy failures, including a 2012 fungal meningitis outbreak linked to contaminated steroid injections that killed 64 patients and injured hundreds, demonstrated what happens when sterile compounding standards are not followed. For patients receiving home IV therapy, USP <797> compliance is not a credential to check once and forget, it reflects the ongoing daily practices of the pharmacy preparing their medications. Patients and providers should verify that any pharmacy preparing their IV solutions is accredited, state-licensed, and actively compliant with current USP standards. How Pharmko Meets These Standards Pharmko's sterile compounding facility is designed, staffed, and operated to meet USP <797> and USP <800> requirements. We are ACHC accredited, state-licensed in 22+ states, and subject to regulatory inspection. Every batch we compound is reviewed by a licensed pharmacist, and our environmental and personnel monitoring data is reviewed on a defined schedule. For a broader overview of what sterile compounding is and how it differs from retail pharmacy, see our guide on what is sterile compounding for IV therapy . For providers interested in our compounding capabilities, see our physician services page or contact our pharmacy team directly. → Contact Pharmko about sterile compounding: 1-877-540-2003

What Is Sterile Compounding and Why Does It Matter for IV Therapy?

May 19, 2026

When a patient needs a medication that is not commercially available in the right dose, formulation, or combination, a sterile compounding pharmacy creates it. Sterile compounding is the process of preparing customized, injectable or infusible medications, IV solutions, eye drops, inhalation solutions, in a controlled, contamination-free environment. Pharmko's sterile compounding services are at the core of what makes specialty pharmacy different from a retail pharmacy. Every IV medication we prepare is custom-compounded, validated, and released by a licensed pharmacist before it reaches a patient. What Makes Compounding 'Sterile'? The word 'sterile' refers to the absence of viable microorganisms, bacteria, fungi, endotoxins, in the final product. This is non-negotiable for any medication injected into or infused through the body. A contaminated IV solution can cause severe bloodstream infections, sepsis, or death. Achieving sterility requires: A controlled cleanroom environment (ISO Class 5 or better at the point of compounding) Positive or negative air pressure depending on the type of medication being prepared Gowning, gloving, and aseptic technique by trained pharmacy staff Validated sterilization methods (filtration, terminal sterilization) appropriate for each formulation Environmental and personnel monitoring to detect contamination risks before they reach patients How Sterile Compounding Differs from Retail Pharmacy A retail pharmacy dispenses commercially manufactured medications in their existing forms — tablets, capsules, pre-made liquids. A sterile compounding pharmacy like Pharmko creates medications that either do not exist commercially, are no longer commercially available, or must be customized for a specific patient. Examples of why sterile compounding is necessary: A patient needs a specific antibiotic concentration not available in commercial vials TPN must be formulated individually based on the patient's weight, labs, and nutritional requirements — no pre-made product covers every case A pediatric patient needs a lower concentration of an IV medication than any commercial product offers IV antibiotics must be prepared in specific volumes and concentrations for OPAT patients based on the prescribed regimen What Is USP <797>? USP <797> is the United States Pharmacopeia chapter that sets the standards for sterile compounding. It defines the environmental requirements, beyond-use dating, testing, personnel training, and quality systems that a pharmacy must maintain to legally compound sterile preparations. Compliance with USP <797> is required by state pharmacy boards and enforced through inspections. Not all compounding pharmacies meet these standards — patients and providers should verify that any pharmacy preparing IV medications is operating in full USP <797> compliance. For a detailed breakdown of what USP <797> and the newer USP <800> standard mean for patient safety, see our guide on sterile compounding safety standards . How Pharmko's Compounding Process Works Pharmko operates a state-of-the-art USP <797> compliant sterile compounding facility. Every product we prepare goes through: Pharmacist review of the prescription for appropriateness, compatibility, and dosing Preparation by trained pharmacy technicians in an ISO Class 5 laminar airflow workbench or biological safety cabinet In-process and final product checks by a licensed pharmacist Sterility testing or filtration validation where required Cold-chain delivery to the patient or dialysis clinic within validated stability windows Why It Matters for Home Infusion Patients Every IV therapy delivered through Pharmko's home infusion services is compounded in our sterile facility. This means patients at home receive the same quality-controlled, pharmacist-verified products they would receive in a hospital — not medications assembled at the bedside or sourced from uncredentialed suppliers. → Contact Pharmko to learn more about our compounding services: 1-877-540-2003